Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR 100 versus THEOLAIR SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR 100 versus THEOLAIR SR.
THEOCLEAR-100 vs THEOLAIR-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator